SGSN Stock Analysis: SGS | SW

Consulting Services | SW, Switzerland | Market Cap: 18.665m CHF | 12M Return: 21.6% | CH1256740924 | Charts, Fundamentals & Technical Analysis

Testing, Inspection, Certification, Consulting
Total Rating 62
Safety 71
Buy Signal -0.04
Consulting Services
Industry Rotation: -11.1
Market Cap: 22.5B
Avg Turnover: 27.7M
Risk 3d forecast
Volatility20.5%
VaR 5th Pctl3.15%
VaR vs Median-5.51%
Reward TTM
Sharpe Ratio0.98
Rel. Str. IBD57.9
Rel. Str. Peer Group71.7
Character TTM
Beta0.343
Beta Downside0.341
Hurst Exponent0.511
Drawdowns 3y
Max DD23.85%
CAGR/Max DD0.49
CAGR/Mean DD1.80

Warnings

Fakeout

Tailwinds

No distinct edge detected

Seasonality 11.7 years of data

Jan +0.7% 8
Feb +0.8% 8
Mar -0.1% 19
Apr +1.1% 5
May +1.3% 31
Jun -0.5% 8
Jul +0.1% 29
Aug -2.9% 58
Sep -0.0% 5
Oct -2.5% 14
Nov +0.5% 27
Dec +0.0% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: SGSN SGS

SGS SA is a Swiss-based testing, inspection, and certification (TIC) company founded in 1878 and headquartered in Baar, Switzerland. It operates globally across Asia Pacific, Europe, North America, Eastern Europe, the Middle East and Africa, and the Americas, organized into two segments: Testing & Inspection and Certification. Its service offering spans agricultural and commodity testing, marine and pre-shipment inspections, product and supply chain certification, sustainability assurance, auditing, regulatory compliance, and professional training.

Classified within the Industrials sector under Research & Consulting Services, SGS serves a diverse client base across agriculture, food, pharma, MedTech, oil and gas, mining, and consumer products. As a TIC provider, SGS typically operates a global network of accredited laboratories and relies on recurring, contract-based revenue tied to regulatory compliance, quality verification, and supply chain risk management for multinational clients.

Headlines to Watch Out For
  • Testing and inspection organic growth tracks mid-single digit target
  • Operational efficiency program supports margin expansion
  • Bolt-on acquisitions expand food and pharma certification footprint
Piotroski VR-10 (Strict) 6.0
Net Income: 663.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.12 > 0.02 and ΔFCF/TA -0.15 > 1.0
NWC/Revenue: -2.26% < 20% (prev 7.68%; Δ -9.94% < -1%)
CFO/TA 0.15 > 3% & CFO 1.25b > Net Income 663.0m
Net Debt (4.51b) to EBITDA (1.58b): 2.85 < 3
Current Ratio: 0.95 > 1.5 & < 3
Outstanding Shares: last quarter (196.0m) vs 12m ago 4.81% < -2%
Gross Margin: 37.25% > 18% (prev 39.43%; Δ -2.18% > 0.5%)
Asset Turnover: 92.08% > 50% (prev 71.98%; Δ 20.11% > 0%)
Interest Coverage Ratio: 10.69 > 6 (EBIT TTM 1.08b / Interest Expense TTM 101.0m)
Altman Z'' 2.10
A: -0.02 (Total Current Assets 3.22b - Total Current Liabilities 3.39b) / Total Assets 8.47b
B: 0.35 (Retained Earnings 3.00b / Total Assets 8.47b)
C: 0.14 (EBIT TTM 1.08b / Avg Total Assets 7.83b)
D: 0.14 (Book Value of Equity 1.01b / Total Liabilities 7.34b)
Altman-Z'' = 2.10 = BBB
Beneish M -2.62
DSRI: 0.89 (Receivables 1.55b/1.26b, Revenue 7.21b/5.17b)
GMI: 1.06 (GM 39.43% / 37.25%)
AQI: 1.29 (AQ_t 0.45 / AQ_t-1 0.35)
SGI: 1.39 (Revenue 7.21b / 5.17b)
TATA: -0.07 (NI 663.0m - CFO 1.25b) / TA 8.47b)
Beneish M = -2.62 (Cap -4..+1) = A
What is the price of SGSN shares?

As of September 27, 2026, the stock is trading at CHF 94.50 with a total of 212,982 shares traded. Over the past week, the price has changed by +1.57%, over one month by +1.09%, over three months by +1.63% and over the past year by +21.64%.

Current recommended Stop Loss: 91.10 (which is 3.6% or 2.4 ATR below the current price).

Is SGSN a buy, sell or hold?

SGS has no consensus analysts rating.

SGS (SGSN) - Fundamental Data Overview as of 26 September 2026
Market Cap USD = 22.5b (18.7b CHF * 1.2066 CHF.USD)
P/E Trailing = 27.7824
P/E Forward = 21.8818
P/S = 2.5902
P/B = 18.5237
P/EG = 5.4756
Revenue TTM = 7.21b CHF
EBIT TTM = 1.08b CHF
EBITDA TTM = 1.58b CHF
Long Term Debt = 3.26b CHF (from longTermDebt, last quarter)
Short Term Debt = 1.52b CHF (from shortTermDebt, last quarter)
Debt = 5.81b CHF (from shortLongTermDebtTotal, last quarter) + Leases 590.0m
Net Debt = 4.51b CHF (calculated: Debt 5.81b - CCE 1.30b)
Enterprise Value = 23.2b CHF (18.7b + Debt 5.81b - CCE 1.30b)
Interest Coverage Ratio = 10.69 (Ebit TTM 1.08b / Interest Expense TTM 101.0m)
EV/FCF = 23.29x (Enterprise Value 23.2b / FCF TTM 995.0m)
FCF Yield = 4.29% (FCF TTM 995.0m / Enterprise Value 23.2b)
FCF Margin = 13.81% (FCF TTM 995.0m / Revenue TTM 7.21b)
Net Margin = 9.20% (Net Income TTM 663.0m / Revenue TTM 7.21b)
Gross Margin = 37.25% ((Revenue TTM 7.21b - Cost of Revenue TTM 4.52b) / Revenue TTM)
Gross Margin QoQ = 36.60% (prev 37.92%)
Tobins Q-Ratio = 2.74 (Enterprise Value 23.2b / Total Assets 8.47b)
Interest Expense / Debt = 1.74% (Interest Expense 101.0m / Debt 5.81b)
Taxrate = 25.13% (239.0m / 951.0m)
NOPAT = 808.6m (EBIT 1.08b * (1 - 25.13%))
Current Ratio = 0.95 (Total Current Assets 3.22b / Total Current Liabilities 3.39b)
Debt / Equity = 5.77 (Debt 5.81b / totalStockholderEquity, last quarter 1.01b)
Debt / EBITDA = 2.85 (Net Debt 4.51b / EBITDA 1.58b)
Debt / FCF = 4.53 (Net Debt 4.51b / FCF TTM 995.0m)
Total Stockholder Equity = 836.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.47% (Net Income 663.0m / Total Assets 8.47b)
RoE = 79.26% (Net Income TTM 663.0m / Total Stockholder Equity 836.5m)
RoCE = 26.34% (EBIT 1.08b / Capital Employed (Equity 836.5m + L.T.Debt 3.26b))
RoIC = 12.94% (NOPAT 808.6m / Invested Capital 6.25b)
WACC = 5.79% (E(18.7b)/V(24.5b) * Re(7.19%) + D(5.81b)/V(24.5b) * Rd(1.74%) * (1-Tc(0.25)))
Discount Rate = 7.19% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -40.44 | Cagr: 1.99%
[DCF] Terminal Value 77.97% ; FCFF base≈938.8m ; Y1≈1.08b ; Y5≈1.58b
[DCF] Fair Price = 97.82 (EV 23.8b - Net Debt 4.51b = Equity 19.3b / Shares 197.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -57.77 | EPS CAGR: -56.35% | SUE: 0.0 | # QB: 0
Revenue Correlation: -21.65 | Revenue CAGR: -3.26% | SUE: 1.13 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=4.12 | Chg30d=+0.04% | Revisions=+35% | GrowthEPS=+7.7% | GrowthRev=+9.2%
EPS next Year (2027-12-31): EPS=4.46 | Chg30d=+0.05% | Revisions=+59% | GrowthEPS=+8.4% | GrowthRev=+6.3%
[Analyst] Revisions Ratio: +52% (up=22, down=6)